FOXO TECHNOLOGIES INC. Research and Development in Process
FOXO TECHNOLOGIES INC. (FOXO) reported Research and Development in Process of $40 for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-11-21
- FOXO TECHNOLOGIES INC. research and development in process for the quarter ending 2022-09-30 was $40.00, a 5.26% increase year-over-year.
- FOXO TECHNOLOGIES INC. research and development in process for the quarter ending 2021-09-30 was $38.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 9 month |
|---|---|---|
| 2022-09-30 | $40.00 10-Q · filed 2022-11-21 | $119.00 10-Q · filed 2022-11-21 |
| 2021-09-30 | $38.00 10-Q · filed 2022-11-21 | $101.00 10-Q · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |